Complementary and alternative medicines in prostate cancer: From bench to bedside?

Oncologist

Volumn 17, Issue 6, 2012, Pages 830-837

  Klempner, Samuel J ^a   Bubley, Glenn ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Complementary and alternative medicine; Curcumin; Green tea; Pomegranate; Prostate cancer; Resveratrol; Silibinin

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CAPECITABINE; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PLACEBO; POLYPHENOL; POMEGRANATE EXTRACT; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RESVERATROL; SELENIUM; SILIBININ; SIRTUIN 1; SOMATOMEDIN BINDING PROTEIN 3; TAXANE DERIVATIVE; VITEX ROTUNDIFOLIA EXTRACT;

ALTERNATIVE MEDICINE; APOPTOSIS; BREAST CANCER; CHRYSANTHEMUM MORIFOLIUM; CLINICAL TRIAL (TOPIC); COLON CANCER; DIET SUPPLEMENTATION; DRUG MEGADOSE; GANODERMA LUCIDUM; GINSENG; GLYCYRRHIZA GLABRA; HERBAL MEDICINE; HUMAN; ISATIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RABDOSIA; RECTUM CANCER; REVIEW; SCUTELLARIA; TEA; XENOGRAFT;

ANTIOXIDANTS; BEVERAGES; COMPLEMENTARY THERAPIES; CURCUMA; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PUNICACEAE; SELENIUM; SILYMARIN; STILBENES; TEA; VITAMIN E; VITAMINS;

EID: 84862881945     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0094     Document Type: Review

References (125)

1. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;12:1-23.
2. Nam RK, Fleshner N, Rakovitch E et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiologic analysis. J Urol 1999;161:1521-1524.
3. McDermott CL, Blough DK, Fedorenko CR et al. Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer 2012;20:65-73.
4. Jacobson JS, Chetty AP. Complementary and alternative medicine in prostate cancer. Curr Oncol Rep 2001;3:448-452.
5. Nahin RL, Barnes PM, Stussman BJ et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009;18:1-14.
6. Klein EA, Thompson IM Jr., Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-1556.
7. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 2004;567:1-61.
8. Cooke MS, Evans MD, Dizdaroglu M et al. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003;17:1195-1214.
9. Tan AC, Konczak I, Sze DM et al. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr Cancer 2011;63:495-505.
10. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004;171:907-910.
11. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63:6988-6995.
12. Neuzil J, Weber T, Gellert N et al. Selective cancer cell killing by a-tocopheryl succinate. Br J Cancer 2001; 84:87-89.
13. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
14. Ganther HE. Selenium metabolism, selenoprotein and mechanisms of cancer prevention: complexities and thioredoxin reductase. Carcinogenesis 1999;20:1657-1666.
15. Combs GF Jr. Status of selenium in prostate cancer prevention. Br J Cancer 2004;91:195-199.
16. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002;168:1578-1582.
17. Qi Y, Schoene NW, Lartey FM et al. Selenium compunds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells. J Biol Chem 2010;285:33010-33017.
18. Langley P. Why a pomegranate? BMJ 2000;321: 1153-1154.
19. Longtin R. The pomegranate: nature's power fruit? J Natl Cancer Inst 2003;95:346-348.
20. Gil MI, Tomas-Barberan FA, Hess-Pierce B et al. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000;48:4581-4589.
21. Seeram NP, Zhang Y, McKeever R et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 2008;11:390-394.
22. Seeram NP, Henning SM, Zhang Y et al. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481-2485.
23. Malik A, Afaq F, Sarfaraz S et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 2005;102: 14813-14818.
24. Irani J, Goujon JM, Ragni E et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54: 467-472.
25. De Marzo AM, Marchi VL, Epstein JI et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155:1985-1992.
26. Domingo-Domenech J, Mellado B, Ferrer B et al. Activation of nuclear factor-kB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005;93:1285-1294.
27. Fradet V, Lessard L, Begin LR et al. Nuclear factor-kB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460-8464.
28. Rettig MB, Heber D, An J et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-KB-dependent mechanism. Mol Cancer Ther 2008;7:2662-2671.
29. Pantuck AJ, Leppert JT, Zomorodian N et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-4026.
30. Kuriyama S, Shimazu T, Ohmori K et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006;296:1255-1265.
31. Katiyar SK, Mukhtar H. Tea in chemoprevention of cancer: epidemiologic and experimental studies. Int J Oncol 1996;8:221-238.
32. Rosenberg L. Coffee and tea consumption in relation to the risk of large bowel cancer: a review of epidemiologic studies. Cancer Lett 1990;52:163-171.
33. Kinlen LJ, McPherson K. Pancreas cancer and coffee and tea consumption: a case-control study. Br J Cancer 1984;49:93-96.
34. Yang G, Zheng W, Xiang YB et al. Green tea consumption and colorectal cancer risk: a report from the Shanghai Men's Health Study. Carcinogenesis 2011;32: 1684-1688.
35. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993;85:1038-1049.
36. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992;21:334-350.
37. Adhami VM, Malik A, Zaman N et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007;13:1611-1619.
38. Park AM, Dong Z. Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol 2003;36:66-77.
39. Chow HH, Cai Y, Alberts DS et al. Phase I pharmacokinetic study of tea polyphenols following singledose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomark Prev 2001; 10:53-58.
40. Chow HH, Cai Y, Hakim IA et al. Pharmacokinetics and safety of green tea polyphenols after multipledose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9:3312-3319.
41. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42:25-54.
42. Jankun J, Selman SH, Swiercz R et al. Why drinking green tea could prevent cancer. Nature 1997;387: 561.
43. Chow HH, Hakim IA, Vining DR et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res 2005;11: 4627-4633.
44. Pisters KM, Newman RA, Coldman B et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19:1830-1838.
45. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999;398:381.
46. Lin JK, Liang YC, Lin-Shiau SY. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 1999;58: 911-915.
47. Yang GY, Liao J, Kim K et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998;19:611-616.
48. Siddiqui IA, Malik A, Adhami VM et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008;27:2055-2063.
49. Liao X, Tang S, Thrasher JB et al. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005;4:505-515.
50. Siddiqui IA, Asim M, Hafeez BB et al. Green tea polyphenolEGCGblunts androngen receptor function in prostate cancer. FASEB J 2011;25:1198-1207.
51. Hastak K, Gupta S, Ahmad N et al. Role of p53 and NF-kB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003;22:4851-4859.
52. Gupta S, Ahmad N, Niemine N et al. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (_)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000;164:82-90.
53. Shammas M, Neri P, Koley H et al. Specific killing of multiple myeloma cells by (_)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006;108:2804-2810.
54. Shimizu M, Deguchi A, Lim JT et al. (_)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005;11:2735-2746.
55. Ahn WS, Huh SW, Bae SM et al. A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. DNACell Biol 2003;22:217-224.
56. Stearns ME, Wang M. Synergistic effects of the green tea extract epigallocatechin-3-gallate in eradication of malignant human prostate tumors. Transl Oncol 2011;4:147-156.
57. Luo T, Wang J, Yin Y et al. (_)-Epigallocatechin gallate sensitizes bre ast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 2010;12:R8. doi:10.1186/bcr2473.
58. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. Clin Cancer Res 1998;4:153-156.
59. Bettuzzi S, Brausi M, Rizzi F et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66: 1234-1240.
60. Jatoi A, Ellison N, Burch PA et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442-1446.
61. Ruby AJ, Kuttan G, Babu KD et al. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995;94:79-83.
62. Ruby AJ, Kuttan G, BabuKDet al. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995;94:79-83.
63. Aggarwal BB, Sundaram C, Malani N et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595:1-75.
64. Hebert JR, Hurley TG, Olendzki BC et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a crossnational study. J Natl Cancer Inst 1998;90:1637-1647.
65. Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
66. Kanai M, Imaizumi A, Otsuka Y et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 2012;69:65-70.
67. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20: 7597-7609.
68. Mukhopadhyay A, Banerjee S, Stafford LJ et al. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002;21:8852-8861.
69. Li M, Zhang Z, Hill DL et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007;67:1988-1996.
70. Yu S, Shen G, Khor TO et al. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008;7:2609-2620.
71. Beevers CS, Li F, Liu L et al. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006;119:757-764.
72. Thangapazham RL, Shaheduzzaman S, Kim KH et al. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol Ther 2008;7:1427-1435.
73. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
74. Hour TC, Chen J, Huang CY et al. Curcumin en hances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIPI and C/EBP_ expressions and suppressing NF-_B activation. Prostate 2002;51:211-218.
75. Bava SV, Puliappadamba VT, Deepti B et al. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-_B and the serine/ threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005;280:6301-6308.
76. Kamat AM, Sethi G, Aggarwal BB et al. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-KB and nuclear factor-KB-regulated gene products in IFN-A-sensitive and IFN-A-resistant human bladder cancer cells. Mol Cancer Ther 2007;6: 1022-1030.
77. Lee JY, Lee YM, Chang GC et al. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One 2011;6:e23756. doi:10.1371/journal.pone.
78. Kunnumakkara AB, Guha S, Krishnan S et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007;67:3853-3861.
79. Ali S, Ahmad A, Banerjee S et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010;70:3606-3617.
80. Anand P, Sundaram C, Jhurani S et al. Curcumin and cancer: an "old-age" disease with an "age-old"solution. Cancer Lett 2008;267:133-164.
81. Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220.
82. Subramanian L, Youssef S, Bhattacharya S et al. Resveratrol: challenges in translation to the clinic-a critical discussion. Clin Cancer Res 2010;16:5942-5948.
83. Shi WF, Leong M, Cho E et al. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One 2009;4:e7398. doi:10.1371/journal.pone.
84. Harada N, Murata Y, Yamaji R et al. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007;53:556-560.
85. Fu M, Liu M, Sauve AA et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 2006;26:8122-8135.
86. Faus H, Haendler B. Androgen receptor acetylation sites differentially regulate gene control. J Cell Biochem 2008;104:511-524.
87. Kuwajerwala N, Cifuentes E, Gautam S et al. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002;62:2488-2492.
88. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004;59:214-225.
89. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A et al. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007;28:282-293.
90. Benitez DA, Pozo-Guisado E, Clementi M et al. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 2007; 96:1595-1604.
91. Chen Q, Ganapathy S, Singh KP et al. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010;5:e15288. doi:10.1371/journal.pone.
92. Park SJ, Ahmad F, Philip A et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phospodiesterases. Cell 2012;148:421-433.
93. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011;1215:9-15.
94. Walle T, Hsieh F, DeLeggeMHet al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32:1377-1382.
95. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003;36:79-87.
96. Rashid A, Liu C, Sanli T et al. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol 2011;6:144-156.
97. Tseng SH, Lin SM, Chen JC et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004;10:2190-2202.
98. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006;231: 113-122.
99. Kimura Y, Okuda H. Resveratrol isolated from polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumorinduced neovascularization in lewis lung carcinoma-bearing mice. J Nutr 2001;131: 1844-1849.
100. Hudson TS, Hartle DK, Hursting SD et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 2007;67:8396-8405.
101. Singh RP, Dhanalakshmi S, Tyagi AK et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor binding protein-3 levels. Cancer Res 2002;62:3063-3069.
102. Wellington K, Jarwis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-489.
103. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-113.
104. Letteron P, Labbe G, Degott C et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol 1990;39:2027-2034.
105. Stattin P, Bylund A, Rinaldi S et al. Plasma insulin-like growth factor-I insulin-like growth factor binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-1917.
106. Zi X, Zhang J, Agarwal R et al. Silibinin upregulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000;60: 5617-5620.
107. Roddam AW, Allen NE, Appleby PE et al. Insulin like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-471.
108. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
109. Tyagi AK, Singh RP, Agarwal C et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002;8:3512-3519.
110. Flaig TW, Su LJ, Harrison G et al. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apotosis in human prostate cancer cells. Int J Cancer 2007;120:2028-2033.
111. Hoh C, Boocock D, Marczylo T et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006;12:2944-2950.
112. Flaig TW, Glode M, Gustafson D et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70:848-855.
113. Chen S, Wang X. Herbal Composition for Treating Prostate Carcinoma. U.S. Patent 5665393. September 9, 1997.
114. Halicka H, Ardelt B, Juan G et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC-SPES. Int J Oncol 1997;11:437-448.
115. Tiwari RK, Geliebter J, Garikapaty VP et al. Antitumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 1999;14:713-719.
116. Oh WK, George DJ, Hackmann K et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen independent prostate cancer. Urology 2001;57:122-126.
117. de la Taille A, Buttyan R, Hayek O et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000; 164:1229-1234.
118. Oh WK, Kantoff PW, Weinberg V et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22:3705-3712.
119. Zyflamend product info. Available at http:// www.newchapter.com/zyflamend/zyflamend#supplementfacts. Accessed 12/7/2011.
120. Bemis DL, Capodice JL, Anastasiadis AG et al. Zyflamend®, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer 2005;52:202-212.
121. Huang EC, Chen G, Baek SJ et al. Zyflamend reduces the expression of androgen receptor in a model of castrate resistant prostate cancer. Nutr Cancer 2011;63: 1287-1296.
122. Sandur SK, Ahn KS, Ichikawa H et al. Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-_B activation and NF-_B-regulated gene products. Nutr Cancer 2007;57:78-87.
123. Yan J, Xie B, Capodice JL et al. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Prostate 2012;72:244-252. doi: 10.1002/pros.21426.
124. Kunnumakkara AB, Sung B, Ravindran J et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer 2011; Sep 20 [E-pub ahead of print]. doi: 10.1002/ ijc.26442.
125. Clement J, Bubley G. Prostasol and venous thromboembolism. Urology 2008;72:664-666.